This appears to result in a better CD8+ T cell tumor response as indicated by higher frequency and number of IT CD8+ T cells with specificity for the melanoma tumor antigen tyrosinase related protein-2 (TRP-2) (TRP-2/Tet+CD8+ T cells) (Figure 4I–K) and higher expression of TNF-α, IFN-γ, and granzyme B (GzmB) in TRP-2/Tet+CD8+ T cells (Figure 4L–N). This evidence concerns the gene DCT and melanoma.